English, Article edition: Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada Michael Iskedjian; Thomas R. Einarson; Bernie J. O'Brien; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/93999
Physical Description
  • article
Language
  • English

Edition details

Title
  • Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada
Author
  • Michael Iskedjian
  • Thomas R. Einarson
  • Bernie J. O'Brien
  • J. Gaston De Serres
  • Ron Gold
  • Ian M. Gemmill
  • Natalie Milkovich
  • Andrew Rosner
Physical Description
  • article
Notes
  • Objective: Pertussis is a highly contagious infection affecting mainly children. Acellular pertussis vaccines were recently introduced in Canada based on evidence of improved safety and efficacy over whole cell vaccines, the current standard of care. The following study reports the economic impact of replacing the whole cell vaccine (wP) by a new acellular vaccine (aP) in the Ontario pertussis immunisation programme. Design: For a hypothetical cohort of 100 000 children from birth to the age of 8 years, the costs and consequences of pertussis vaccination with either aP or wP were compared. A decision analytical model was constructed for vaccine delivery, treatment of pertussis cases and vaccine adverse events, with analyses from the viewpoints of the Ontario Ministry of Health and society. Main outcome measures and results: The main outcomes were expected number of pertussis cases, hospitalisations, and workdays lost by parents. Data on vaccine effectiveness, pertussis incidence, and other parameters used in the model were from published literature. Costs were discounted at 5%, and extensive sensitivity analyses were undertaken. Over 8 years, in a cohort of 100 000 children, the introduction of aP would prevent 10 500 cases of pertussis, avoiding 504 hospital admissions and 73 500 days of work absence. For Ontario, healthcare cost savings over the same period would amount to 275 585 Canadian dollars ($Can), and societal savings to $Can9 752 864 (1997 values). Results were sensitive to both incidence of pertussis and vaccine efficacy. Conclusion: This study suggests that even though the new acellular vaccine has a higher acquisition cost than the current whole cell vaccine, its improved efficacy and safety result in overall cost savings.
  • Children, Cost analysis, Hib DTaP poliovirus vaccine, Hib DTP poliovirus vaccine, Infants, Pertussis, Pharmacoeconomics, Research and development, Vaccines
  • RePEc:wkh:phecon:v:19:y:2001:i:5:p:551-563
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment